Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Fun in the Sun: The Benefits of Vitamin D

Samantha C. Shapiro, MD  |  Issue: December 2024  |  November 23, 2024

So how long does the small, protective effect of vitamin D last? Or as our patients often ask, “Do I have to take this for the rest of my life?” Data show that the answer is yes. “After you stop taking it, the effect dissipates pretty quickly unfortunately,” she said.5

As with all studies, there are limitations. Dr. Costenbader explained, “Since this was just one big trial, it can’t answer all the questions we have about vitamin D for our diseases. This wasn’t a high-risk or vitamin D deficient population, where the effect may be even greater. We only studied older adults (men 50 years of age or older and women 55 years of age or older), so the effect in younger populations remains to be proven. And, we did have difficulty confirming incident autoimmune thyroid disease in particular since this diagnosis is often made without testing for autoantibodies.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

As for strengths, Dr. Costenbader noted, “This was the first large, nationwide, double-blind randomized controlled trial for the prevention of autoimmune disease in the general population. Vitamin D is a well-tolerated, non-toxic supplement, and nothing else has been shown to reduce the overall incidence of autoimmune disease yet. It was safe without an increase in adverse events, and two-year extension assessed prolonged effects. I think it has high clinical importance.”

Treatment Effects in Rheumatic Disease

Some recent meta-analyses speak to the potential effect of vitamin D supplementation in RA and SLE.6,7 Varying doses and durations of vitamin D supplementation have been tested. “There were no strong or consistent effects observed, though there may possibly be small benefits on pain and DAS-CRP. The evidence isn’t strong,” Dr. Costenbader said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Conclusion

To summarize, vitamin D deficiency is very common in most all inflammatory conditions. Long-term use of vitamin D3 2,000 IU daily was safe and reduced the incidence of all autoimmune diseases by 22% after two to three years, but the effect dissipates quickly after cessation of vitamin D.4 Varying doses and durations of vitamin D have been tested for the treatment of SLE and RA, but no strong or consistent effect has been observed. And last but not least, supplementation for patients with vitamin D deficiency to prevent bone loss is still recommended.


A sidebar by Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS

Calcium Absorption

Sylvia Christakos, PhD, professor in the Department of Biochemistry and Molecular Biology, Rutgers New Jersey Medical School, Newark, discussed calcium absorption and homeostasis in the aging individual. She noted that in mouse models, vitamin D receptor (VDR)–knockout mice developed hypocalcemia and rickets, but when given a rescue diet high in calcium, rickets can be prevented. This suggests that the decreased effect of vitamin D (and its active form, 1,25-dihydroxy-vitamin D) is largely in the absorption of calcium for the gut.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsOther Rheumatic ConditionsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR Convergence 2024

Related Articles

    Drug Updates

    November 1, 2009

    Information on News Approvals and Medication Safety

    Improve RA Care with Vitamin D

    November 16, 2015

    Background Autoimmune diseases, such as rheumatoid arthritis (RA) and systemic lupus erythema­tous, occur when the body attacks its own tissue because it cannot differentiate between self and non-self. This is mainly through deregulation of the immune system. Vitamin D has been known to play a critical role in bone mineralization and bone health. Activated vitamin…

    Vitamin D in Rheumatology: Cause and Effect Unclear

    September 15, 2015

    The controversy over vitamin D is hearty enough to confuse even seasoned rheumatologists, says Nathan Wei, MD, The Arthritis Treatment Center, Frederick, Md. “It’s like what you hear with coffee. One week, [a study finds] coffee is … good for you; the next week, there’s a study saying it’s bad for you,” he says. ad…

    Clinical Rheumatology Year in Review 2021

    November 22, 2021

    ACR Convergence 2021—On Nov. 5, Karen H. Costenbader, MD, MPH, professor of medicine, Harvard Medical School, and director of the lupus program, Brigham and Women’s Hospital, Boston, gave a whirlwind review of the most important clinical rheumatology publications of the past year. Testing New Medications for Rheumatic Disease ADVOCATE Trial of Avacopan ad goes here:advert-1ADVERTISEMENTSCROLL…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences